These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

998 related articles for article (PubMed ID: 18371137)

  • 21. Intravenous versus oral iron therapy for postpartum anaemia.
    Bhandal N; Russell R
    BJOG; 2006 Nov; 113(11):1248-52. PubMed ID: 17004982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP).
    Breymann C; Milman N; Mezzacasa A; Bernard R; Dudenhausen J;
    J Perinat Med; 2017 May; 45(4):443-453. PubMed ID: 27278921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Bailie GR; Mason NA; Valaoras TG
    Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S; Maltez C; Lopes AI
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia.
    Westad S; Backe B; Salvesen KA; Nakling J; Økland I; Borthen I; Rognerud Jensen OH; Kolås T; Løkvik B; Smedvig E
    Acta Obstet Gynecol Scand; 2008; 87(9):916-23. PubMed ID: 18720044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
    J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study.
    Kim YH; Chung HH; Kang SB; Kim SC; Kim YT
    Acta Haematol; 2009; 121(1):37-41. PubMed ID: 19332985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis.
    Hershko C; Ianculovich M; Souroujon M
    Acta Haematol; 2007; 118(1):19-26. PubMed ID: 17426393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
    Bregman DB; Morris D; Koch TA; He A; Goodnough LT
    Am J Hematol; 2013 Feb; 88(2):97-101. PubMed ID: 23335357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
    Breymann C; Gliga F; Bejenariu C; Strizhova N
    Int J Gynaecol Obstet; 2008 Apr; 101(1):67-73. PubMed ID: 18234203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease.
    Erichsen K; Ulvik RJ; Nysaeter G; Johansen J; Ostborg J; Berstad A; Berge RK; Hausken T
    Scand J Gastroenterol; 2005 Sep; 40(9):1058-65. PubMed ID: 16165718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
    Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
    Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease.
    Gisbert JP; Gomollón F
    Am J Gastroenterol; 2008 May; 103(5):1299-307. PubMed ID: 18477354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.
    Pfenniger A; Schuller C; Christoph P; Surbek D
    J Perinat Med; 2012 Apr; 40(4):397-402. PubMed ID: 22752771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
    Evstatiev R; Alexeeva O; Bokemeyer B; Chopey I; Felder M; Gudehus M; Iqbal T; Khalif I; Marteau P; Stein J; Gasche C;
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.